Get the Stockscreener App
4.17
0.71%
-0.03
Pre-market:
4.20
0.03
+0.72%
Annexon Inc stock is traded at $4.17, with a volume of 1.21M.
It is down -0.71% in the last 24 hours and down -20.27% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$4.20
Open:
$4.24
24h Volume:
1.21M
Relative Volume:
0.89
Market Cap:
$444.49M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-2.3559
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-7.95%
1M Performance:
-20.27%
6M Performance:
-25.93%
1Y Performance:
-3.92%
1-Day Range:
$4.105
$4.28
1-Week Range:
$3.95
$4.71
52-Week Range:
$3.86
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.17 | 444.49M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Guillain-Barré Syndrome Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Chafic Karam, Hansa Biopharma AB, Annexon - The Globe and Mail
Guillain-Barre Syndrome Market to Reach New Heights in Growth - openPR
Annexon (NASDAQ: ANNX) Issues Press Release Outlining 2025 Outlook - Defense World
Hennion & Walsh Asset Management Inc. Boosts Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Barclays PLC Boosts Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - GlobeNewswire
Annexon Advances Three Breakthrough Therapies, Including First Targeted GBS Treatment - StockTitan
JPMorgan Chase & Co. Has $10.10 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Expands Board with Appointment of New Member William Jones - Defense World
Annexon Biosciences Strengthens Board for Strategic Growth - TipRanks
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - GlobeNewswire
Annexon Strengthens Board with Commercial Veteran BJ Jones Ahead of Late-Stage Drug Launches - StockTitan
ANNXAnnexon, Inc. Latest Stock News & Market Updates - StockTitan
Jane Street Group LLC Sells 39,601 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles (NASDAQ:ANNX) - Seeking Alpha
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Annexon (NASDAQ:ANNX) Stock Price Down 4.3%Here's Why - MarketBeat
Franklin Resources Inc. Acquires Shares of 49,406 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Barclays PLC Has $1.05 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Geode Capital Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by State Street Corp - Defense World
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment - TipRanks
State Street Corp Has $22.74 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
New Data Supports BLA Package - Streetwise Reports
Annexon (NASDAQ:ANNX) Given Buy Rating at HC Wainwright - MarketBeat
Annexon shares rise on positive Guillain-Barré study results By Investing.com - Investing.com Australia
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Awards Major Stock Options Package to New Hires in Strategic Talent Acquisition Move - StockTitan
Annexon shares rise on positive Guillain-Barré study results - Investing.com
Annexon (NASDAQ:ANNX) Shares Gap UpWhat's Next? - MarketBeat
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - The Manila Times
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 - The Bakersfield Californian
Annexon's ANX005 Shows Breakthrough Results in Guillain-Barré Treatment, Outperforms Standard Therapy - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
The Manufacturers Life Insurance Company Buys 2,450 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
MetLife Investment Management LLC Acquires 5,814 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Intech Investment Management LLC Purchases Shares of 26,013 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Fmr LLC - Defense World
Fmr LLC Has $50.69 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Holdings Lowered by Point72 Asset Management L.P. - MarketBeat
Readystate Asset Management LP Reduces Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting - The Manila Times
Annexon to Present Phase 2 ARCHER Data on Protection of - GlobeNewswire
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):